natgillin/translations-raw huggingface dataset:
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Nezmožnost, da se uprete dražljaju, težnji ali skušnjavi po opravljanju določenih aktivnosti, ki lahko škodujejo vam ali drugim.
Inability to sleep
nespečnost
inability to sleep
nezmožnost spanja
inability to sleep (insomnia)
nespečnost
inability to sleep (insomnia)
nespečnost (insomnija)
inability to sleep (insomnia)
nespečnost,
inability to sleep (insomnia)
nezmožnost zaspati (nespečnost)
inability to sleep (insomnia); cough; dyspnoea (breathing difficulties).
nespečnost (insomnija), kašelj, dispneja (težko dihanje).
inability to sleep headache
nezmožnost spanja glavobol
inability to sleep,
nespečnost,
inability to sleep,
nezmožnost spanja,
Inability to sleep, depression, changed sense of taste
nezmožnost spanja, depresija, spremenjeno okušanje
inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness
nespečnost, halucinacije, zmedenost, nenormalne sanje (vključno z nočnimi morami), utrujenost
inability to sleep, hallucinations, confusion, abnormal dreams (including nightmares), tiredness
nespečnost, halucinacije, zmedenost, nenormalne sanje (vključno z nočnimi morami), utrujenost
Inability to speak or write or understand spoken or written language
nezmožnost govora, pisanja ali razumevanja izgovorjenih ali napisanih besed,
Inability to speak or write or understand spoken or written language;
nezmožnost govora, pisanja ali razumevanja izgovorjenih ali napisanih besed,
Inability to stand or sit upright for at least 30 minutes.
Nesposobnost stati ali sedeti vzravnano vsaj 30 minut.
Inability to stand or sit upright for at least 60 minutes
Nesposobnost stanja ali vzravnanega sedenja vsaj 60 minut.
Inability to stand or sit upright for at least 60 minutes
Nesposobnost stati ali pokončno sedeti vsaj 60 minut
Inability to stand or sit upright for at least 60 minutes
Nezmožnost stanja ali pokončnega sedenja vsaj 60 minut.
inability to sweat normally
težave z normalnim potenjem,
inability to taste (ageusia)
izguba zmožnosti okušanja (agevzija)
Inability to tolerate alcohol consumption
nezmožnost prenašanja alkohola
Inability to urinate
nezmožnost uriniranja;
Inability to walk due to imbalance Inflammation of pancreas or intestine Loss of memory
nezmožnost hoje zaradi motnje ravnotežja; vnetje trebušne slinavke ali črevesa; izguba spomina;
Inactivated
EU/2/11/131/006
Inactivated
Inaktiviran
Inactivated B.bronchiseptica, strain 833CER
Inaktivirani sev bakterije Bordetella bronchiseptica, 833CER,
Inactivated Bluetongue Virus ......................................... strain specific pass level (log10 pixels) ** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktiviran virus bolezni modrikastega jezika (BTV) ≥ sev specifičen nivo (log10 pikslov)** (*) Največ dva različna inaktivirana serotipa virusa bolezni modrega jezika
Inactivated Bluetongue Virus Serotype 1................................................................. 1.9 log10 pixels* (*) Antigen content (VP2 protein) by immuno-assay
.Virus bolezni modrikastegaga jezika (BTV), serotip 1, inaktiviran..................... ≥ 1.9 log10 pikslov* (*) Vsebnost antigena (VP2) protein) z imunološkimi metodami
Inactivated Bluetongue Virus, serotype 1, strain BTV- 1/ALG2006/01 E1 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 1, sev BTV- 1/ALG2006/
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 Aluminium hydroxide, saponin and thiomersal.
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 Aluminijev hidroksid, saponin in tiomersal.
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 Aluminium hydroxide, saponin and thiomersal.
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1, aluminijev hidroksid, saponin in tiomersal.
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 Inaktiviran virus modrega jezika, serotip 8, sev BTV-8/BEL2006/02
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP* ≥ 1
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP*≥1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP* ≥ 1 Inaktiviran virus modrega jezika, serotip 8, sev BTV-8/BEL2006/02 RP* ≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1, Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP* ≥ 1 Inaktiviran virus modrega jezika, serotip 8, sev BTV-8/BEL2006/02 RP* ≥ 1
Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiviran virus modrega jezika, serotip 8, sev BTV-8/BEL2006/02 RP* ≥ 1
Inactivated Bluetongue Virus............................................ strain specific pass level (log10 pixels)** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktiviran virus bolezni modrikastega jezika (BTV) ≥ sev specifičen nivo (log10 pikslov)** (*) Največ dva različna inaktivirana serotipa virusa bolezni modrega jezika
Inactivated Bordetella bronchiseptica, strain 833CER: .............................................
Inaktivirani sev bakterije Bordetella bronchiseptica, 833CER :................................
Inactivated Bordetella pertussis 2 not less than 4 International Units Hepatitis B surface antigen (rDNA) 2, 3 10 micrograms Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2 2.5 micrograms conjugated to tetanus toxoid as a carrier 5-10 micrograms
Inaktivirana bakterija Bordetella pertussis2 ne manj kot 4 mednarodne enote Rekombinantni površinski antigen virusa hepatitisa B2, 3 10 mikrogramov Polisaharid bakterije Haemophilus influenzae tipa b (poliribozilribitol-fosfat)2 2,5 mikrograma konjugiran na tetanusni toksoid kot nosilec 5 – 10 mikrogramov
Inactivated Bordetella pertussis 2  4 IU
Inaktivirana bakterija Bordetella pertussis2 ≥ 4 i.e.
Inactivated Bordetella pertussis strain**  4 IU
davični toksoid* ≥ 30 i.e.
Inactivated BTV .......................................................................... strain specific pass level (log10 pixels) The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet.
Tip seva (največ dva seva), ki je vključen v končno zdravilo je potrebno določiti glede na epidemiološko situacijo ob času proizvodnje cepiva in bo označen na pakiranju in v navodilu za uporabo.
Inactivated BTV 1 ....................................................................................................... 1.9 log10 pixels
BTV 1, inaktiviran .................................................................................................  1,9 log10 pikslov
Inactivated BTV 1 ...................................................................................................... 1.9 log10 pixels
Inaktiviran BTV 1, inaktiviran ............................................................................... ≥ 1,9 log10 pikslov
Inactivated BTV1 ..................................................................................................... 1.9 log10 pixels*
Inaktiviran BTV 1, inaktiviran ............................................................................. ≥ 1,9 log10 pikslov
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU Iscom-Matrix
Inaktiviran himerični sev flavivirusa YF-WN ≥ 492 AU Iscom-Matrix
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU1
Inaktiviran himerični sev flavivirusa YF-WN ≥ 492 AU1
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units*
Inaktivirana Coxiella burnetii, sev Nine Mile > 72 QF enot
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units*
Inaktivirana Coxiella burnetii, sev_Nine Mile > 72 QF enot
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units/ml
Inaktivirana Coxiella burnetii, sev_Nine Mile > 72 QF enot*/ml
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ....................
inaktivirano bakterijo Erysipelothrix rhusiopathiae, sev R32E11 .
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, .....................
Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 .
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ......................
Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 ....
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, .........................
Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 ....
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ELISA > 3.34 IE50%
Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 ELISA >
Inactivated Erysipelothrix rhusiopathiae, strain R32E11: ELISA > 3.34 IE50%**.
Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 ELISA >
Inactivated feline Calicivirosis
antigeni kalici virusa mačk (sev FCV
Inactivated feline Calicivirosis
Inaktivirani antigeni kalici virusa
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U.
Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1) .......................  2,0 enot v testu ELISA
Inactivated feline calicivirus (FCV 431 and G1 strains) antigens...................................  2.0 ELISA U.
Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1) .........................  2,0 enot v testu ELISA
Inactivated foot-and-mouth disease antigen, at least 6 cattle PD50 per strain.
Inaktivirani antigeni virusa slinavke in parkljevke, vsaj 6 ZO50 za govedo na sev
Inactivated foot-and-mouth disease antigen, at least 6 cattle PD50 per strain.
Prečiščeni, inaktivirani antigeni virusa slinavke in parkljevke, vsaj 6 ZO50 za govedo na sev
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Inaktivirani antigeni v cepivu so prečiščeni in ne vsebujejo dovolj ne-strukturnih proteinov (NSP), da bi izzval odziv protiteles po dajanju trivalentnega cepiva, ki vsebuje vsaj 15 PD50 antigena na posamezni sev na 2 ml odmerek.
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Inaktivirani antigeni v cepivu so prečiščeni in ne vsebujejo dovolj ne-strukturnih proteinov (NSP), da bi izzvali odziv protiteles po dajanju trivalentnega cepiva, ki vsebuje vsaj 15 PD50 antigena na posamezni sev na 2 ml odmerek.
Inactivated FPV (RP 8.50–12.25); FCV (RP 1.26–2.40); FVR (RP 1.39–2.10); Chlam (RP 1.69–3.50); FeLV (RP 1.45–2.00).
Inaktiviran FPV (R.P. 8,50 – 12,25); FCV (R.P. 1,26 – 2,40); FVR (R.P. 1,39 – 2,10); Chlam (R.P. 1,69 – 3,50); FeLV (R.P. 1,45 – 2,0)
Inactivated Leptospira strains*
Inaktivirani sevi leptospire
Inactivated Leptospira strains:
Inaktivirani sevi bakterije Leptospira:
Inactivated Mycoplasma hyopneumoniae strain P-5722-3
Inaktivirana Mycoplasma hyopneumoniae, sev P-5722-3
inactivated polioviruses.
inaktivirane polioviruse.
inactivated polioviruses; polysaccharides (sugars) from the bacterium Haemophilus influenzae type b (‘Hib’, a bacterium that causes meningitis).
inaktivirane polioviruse; polisaharide (sladkorje) iz bakterije Haemophilus influenzae tipa b (Hib, bakterije, ki povzroča meningitis).
Inactivated porcine circovirus type 2 (PCV2) .................................................  1.8 log10 ELISA Units
Inaktiviran prašičji cirkovirus tip 2 (PCV2)........................................................  1.8 log10 ELISA.enot
Inactivated porcine parvovirus, strain NADL-2, .....................................................
inaktiviran prašičji parvovirus, sev NADL-2 ..........................................................
Inactivated porcine parvovirus, strain NADL-2, .......................................................
Inaktiviran prašičji parvovirus, sev NADL-2 ............................................................
Inactivated porcine parvovirus, strain NADL-2: RP* > 1.15,
Inaktiviran prašičji parvovirus, sev NADL-2 RP > 1,15
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 ≥70% cELISA40
Inaktivirani virus hemoragične bolezni kuncev tipa 2 (RHDV2), sev V-1037 ≥70% cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037: ≥70% cELISA40*
Inaktivirani virus hemoragične bolezni kuncev tipa 2 (RHDV2), sev V-1037: ≥70 % cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strainV-1037 ≥70% cELISA40* (*) ≥70 % of vaccinated rabbits shall give cELISA antibody titres equal to or higher than 40.
Inaktivirani virus hemoragične bolezni kuncev tipa 2 (RHDV2), sev V-1037: ≥70% cELISA40* (*) ≥ 70 % cepljenih kuncev bo imelo titer protiteles cELISA 40 ali več.
Inactivated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU***
Inaktiviran virus stekline, sev SAD Vnukovo-32 ≥ 2,0 IU
Inactivated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU***
Inaktivirani virus stekline, sev SAD Vnukovo-32 ≥ 2,0 IU
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ck/VN/C58/04) > 1:40 HI Units
Inaktiviran rekombinantni virus aviarne influence podtipa H5N3 (sev rg-A/ck/VN/C58/04) > 1:40 HI Enot
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ck/VN/C58/04) > 1:40 HI Units Water in oil adjuvant
Neaktiviran rekombinantni virus aviarne influence podtipa H5N3 (sev rg-A/ck/VN/C58/04) > 1:40 HI Enot Voda v oljnem dodatku
Inactivated recombinant chimeric PCV type 1 containing the PCV type 2 ORF2 protein
Inaktiviran rekombinanten prašičji cirko virus tip I z izraženim proteinom ORF2 prašičjega cirkovirusa tipa 2
Inactivated recombinant chimeric porcine circovirus type 1containing the porcine circovirus type 2 ORF2 protein
Inaktiviran rekombinanten prašičji cirko virus tip I z izraženim proteinom ORF2 prašičjega cirkovirusa tipa 2
Inactivated recombinant Porcine Circovirus type 1 expressing the Porcine Circovirus type 2 ORF2 protein 1.6  RP  5.3
Inaktiviran rekombinanten prašičji cirkovirus tipa 1 z izraženim proteinom ORF2 prašičjega cirkovirusa tipa 2 1.6  RP  5.3
Inactivated RHDV2, strain V-1037: ≥70% cELISA40
Inaktivirani RHDV2, sev V-1037: ≥70% cELISA40
Inactivated Schmallenberg virus (RP ≥ 1/dose)
Inaktivirani virus Schmallenberg (RP ≥ 1/odmerek)
Inactivated type 1 poliovirus ..................................................................
Inaktiviran poliovirus tipa 1....................................................................
Inactivated type 1 poliovirus 40 DU
tetanusni toksoid, adsorbiran  40 i.e.
Inactivated type 2 poliovirus ..................................................................
Inaktiviran poliovirus tipa 2....................................................................
Inactivated type 3 poliovirus ..................................................................
Inaktiviran poliovirus tipa 3....................................................................
Inactivated viral vaccine, to stimulate active immunity against bluetongue virus serotype 8.
Inaktivirano virusno cepivo za vzbujanje aktivne imunosti proti serotipu 8 virusa bolezni modrikastega jezika
Inactivated West Nile virus, strain VM-2 (1.0–2.2 RP).
Inaktiviran virus West Nile, sev VM-2 (1,0–2,2 RP)
Inactivated West Nile virus, strain VM-2 RP* 1.0–2.2
Inaktiviran virus West Nile, sev VM-2 RP* 1,0-2,2
Inactivated West Nile virus, strain VM-2.
Inaktiviran virus West Nile, sev VM-2
Inactivated whole cell suspension of O. rhinotracheale
Inaktivirana suspenzija celic bakterije O. rhinotracheale
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A strain B3263/91 1 x 107 cells *
Inaktivirana suspenzija celic bakterije Ornithobacterium rhinotracheale, serotip A, sev B3263/91 1 x 107 celic
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A, strain B3263/91 1 x 107 cells *
Inaktivirana suspenzija celic bakterije Ornithobacterium rhinotracheale, serotip A, sev B3263/91 1 x 107 celic
Inactive disease
neaktivna bolezen
inadequate asthma control and in frequent need of a reliever inhaler. asthma exacerbations in the past requiring medical intervention.
z neustrezno nadzorovano astmo, ki pogosto potrebujejo inhalator z olajševalcem. s poslabšanjem astme v preteklosti, pri katerem je bila potrebna medicinska intervencija.
Inadequate dosage or discontinuation of treatment, especially in type 1 diabetes, may lead to
Neustrezno odmerjanje ali prekinitev zdravljenja lahko, zlasti pri diabetesu tipa 1, povzroci
Inadequate dosing and/or discontinuation of anti-diabetic treatment may lead to hyperglycaemia and potentially to hyperosmolar coma.
Neustrezno odmerjanje in/ali prekinitev zdravljenja povzroči hiperglikemijo in morebiti tudi hiperosmolarno komo.
Inadequate factor IX recovery p, *
nezadosten porast faktorja IXp,
inadequate food intake,
nezadostno uživanje hrane,
Inadequate response
Nezadosten odziv
Inadequate Response to Methotrexate
Nezadosten odziv na metotreksat
Inadequate Response to MTX
Nezadosten odziv na MTX
Inadequate Response to TNF Inhibitor
Nezadosten odziv na zaviralec TNF
Inadequate therapeutic response*
nezadosten odziv na zdravljenje
Inadvertent administration of an 0.5 ml dose of IXIARO in children aged 1 to <3 years does not pose any safety concerns (section 5.1.).
Nenamerno injiciranje odmerka 0,5 ml cepiva IXIARO otrokom, starim 1 do < 3 leta ne predstavlja razloga za skrb zaradi varnosti (poglavje 5.1.).
Inadvertent intravascular injection could lead to thromboembolic event and disseminated intravascular coagulation (DIC), and there is also a risk of anaphylactic reaction (see section 4.4).
Nenamerno intravaskularno injiciranje lahko povzroči trombembolični dogodek in diseminirano intravaskularno koagulacijo, prav tako pa obstaja tveganje za anafilaktično reakcijo (glejte poglavje 4.4).
Inadvertent intravascular injection could lead to thromboembolic event and disseminated intravascular coagulation (DIC), and there is also a risk of anaphylactic reaction (see Section 4.4).
Nenamerno intravaskularno injiciranje lahko povzroči tromboembolični dogodek in diseminirano intravaskularno koagulacijo, prav tako pa obstaja tveganje za anafilaktično reakcijo (glejte poglavje 4.4).
Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe.
Nepazljivo, nenamerno ali nenadzorovano zamenjevanje zdravil s takrolimusom v farmacevtskih oblikah, s takojšnjim ali podaljšanim sproščanjem, ni varno.
inal
ilo
inappropriate antidiuretic hormone secretion
motnje v izločanju antidiuretičnega hormona,
Inappropriate antidiuretic hormone secretion*
neustrezno izločanje antidiuretičnega hormona
Inappropriate antidiuretic hormone secretion*
neustrezno izločanje antidiuretičnega hormona*,
inappropriate antidiuretic hormone secretion1
neustrezno izločanje antidiuretičnega hormona1
inappropriate antidiuretic hormone secretionc, glucose urine present
motnje v izločanju antidiuretičnega hormonac, prisotnost glukoze v urinu
Inappropriate behaviour.
Neprimerno vedenje.
inappropriate secretion of a hormone that controls urine volume
nepravilno izločanje hormona, ki uravnava količino urina
inappropriate secretion of a hormone that controls urine volume, sugar in the urine
neustrezno sproščanje hormona, ki uravnava količino izločenega urina, prisotnost sladkorja v urinu
Incidenc e rate per 100 patient- years*
Pojavnost na 100 bolnik-let
Incidence
Pogostnost
Incidence (%)
10.1 % (Z)
Incidence (%)
pojavnost (%)
Incidence (%) of confirmed nocturnalc hypoglycaemia (n/Total N)
Incidenca (%) potrjenihb hipoglikemij (n/celotni N)
Incidence (%) of severea hypoglycaemia (n/Total N)
Incidenca (%) hudiha hipoglikemij (n/celotni N)
Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.
Incidenca in resnost neželenih učinkov, povezanih z osrednjim živčnim sistemom in prebavili, sta se običajno s časom zmanjševali.
Incidence at Baseline n (%)a
incidenca ob začetku študije n (%)a
Incidence Category
Razred pogostnosti
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Pogostnosti neželenih učinkov iz kontroliranih kliničnih študij in iz obdobja trženja zdravila so:
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Pogostnosti neželenih učinkov, zabeleženih v kontroliranih kliničnih študijah in postmarketinških izkušnjah, so:
Incidence of adverse reactions with Fabrazyme treatment
Pogostnost neželenih učinkov pri zdravljenju z zdravilom Fabrazyme
Incidence of autograft
Incidenca avtotransplantata
Incidence of clinical vertebral fracture
Incidenca kliničnih zlomov vretenc
Incidence of clinical vertebral fracture
Incidenca novih zlomov vretenc
Incidence of death from “Progressive disease” was 18% in the subcutaneous group and 9% in the intravenous group.
Incidenca smrti zaradi napredovanja bolezni je bila v subkutani skupini 18 % in v intravenski skupini 9 %.
Incidence of death from “Progressive disease” was 18% in the subcutaneous group and 9% in the intravenous group.
Incidenca smrti zaradi napredovanja bolezni je bila v subkutani skupini 18% in v intravenski skupini 9%.
Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population)
MI po oceni KKP (populacija “zdravljena v skladu z razporeditvijo v skupine”)
Incidence of hypoglycaemia at endpoint
Končna incidenca hipoglikemije
Incidence of laboratory abnormalities in TT01 and TT02 (n=80 patients)
Pojavnost nenormalnosti rezultatov laboratorijskih preiskav v TT01 in TT02 (n=80 bolnikov)
Incidence of relapses at 10 years was reduced in patients receiving TAC compared to those who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6% (p = 0.0043).
Pogostost recidiva pri 10 letih je bila zmanjšana pri bolnicah, ki so prejemale TAC, v primerjavi s tistimi, ki so prejemale FAC (39 % proti 45 %) t.j. zmanjšanje absolutnega tveganja za 6 % (p = 0,0043).
Incidence of relapses at 10 years was reduced in patients receiving TAC compared to those who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6% (p = 0.0043).
Pogostost recidiva pri 10 letih je bila zmanjšana pri bolnicah, ki so prejemale TAC, v primerjavi s tistimi, ki so prejemale FAC (39 % proti 45 %) t.j. zmanjšanje absolutnega tveganja za 6 % (p = 0.0043).
Incidence of relapses at 10 years was reduced in patients receiving TAC compared to those who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6% (p=0.0043).
Pogostost relapsa po 10 letih je bila zmanjšana pri bolnicah, ki so dobivale TAC, v primerjavi s tistimi, ki so dobivale FAC (39 % proti 45 %) t.j. zmanjšanje absolutnega tveganja za 6 % (p = 0,0043).
Incidence of relapses at 5 years was reduced in patients receiving TAC compared to those who received FAC (25% versus 32%, respectively) i.e. an absolute risk reduction by 7% (p=0.001).
Pogostost recidiva pri 5 letih je bila zmanjšana pri bolnicah, ki so prejemale TAC, v primerjavi s tistimi, ki so prejemale FAC (25 % proti 32 %) t.j. zmanjšanje absolutnega tveganja za 7 % (p = 0,001).
Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
Incidenca sistemskih neželenih učinkov ob lokalni uporabi v očesu je nižja kot pri sistemski uporabi.